The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

Citations

Citations to this article as recorded by  

• Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications
  Neha V. Bhilare, Rushikesh Shedge, Prashant M. Tambe, Ajinkya More
  Medicinal Chemistry Research.2024; 33(3): 337.     CrossRef
• Simultaneous Estimation of Repaglinide and Voglibose in Newly Approved Fixed-Dose Combination by using UFLC: Application to ICH Q14 Concept and Comparative Method Greenness Assessment
  S.S. Panda, P.C. Rauta, V.S. Pulusu, S. Sahu, B.B. Dash
  Asian Journal of Chemistry.2023; 35(4): 887.     CrossRef
• Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
  Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya, Kumar Gaurav
  International Journal of Diabetes in Developing Countries.2023; 43(6): 856.     CrossRef
• The Gut Microbiome, Metformin, and Aging
  Sri Nitya Reddy Induri, Payalben Kansara, Scott C. Thomas, Fangxi Xu, Deepak Saxena, Xin Li
  Annual Review of Pharmacology and Toxicology.2022; 62(1): 85.     CrossRef
• Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial
  Wajiha Mahjabeen, Dilshad Ahmed Khan, Shakil Ahmed Mirza
  Complementary Therapies in Medicine.2022; 66: 102819.     CrossRef
• Letrozole: Pharmacology, toxicity and potential therapeutic effects
  Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Dhanushya Nagarajan, Vibhaa K K, Anagha V, Joshua Paul P, Tharani Priya T, Rituraj Chakraborty, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Abilash Valsala Gopalakrishnan
  Life Sciences.2022; 310: 121074.     CrossRef
• Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
  Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
  Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
• Treatment intensification in type 2 diabetes management after the failure of two oral hypoglycemic agents: A non‐interventional comparative study
  Sirajudeen Shaik Alavudeen, Sultan M. Alshahrani, Easwaran Vigneshwaran, Noohu Abdulla Khan, Javid I. Mir, Abubakr T. M. Hussein
  International Journal of Clinical Practice.2021;[Epub]     CrossRef
• Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus
  Antonios Kousaxidis, Anthi Petrou, Vasiliki Lavrentaki, Maria Fesatidou, Ioannis Nicolaou, Athina Geronikaki
  European Journal of Medicinal Chemistry.2020; 207: 112742.     CrossRef
• Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86)
  Hannah Seok, Tae Seo Sohn
  Diabetes & Metabolism Journal.2019; 43(4): 545.     CrossRef
• A Survey of the Structures of US FDA Approved Combination Drugs
  Pradipta Das, Michael D. Delost, Munaum H. Qureshi, David T. Smith, Jon T. Njardarson
  Journal of Medicinal Chemistry.2019; 62(9): 4265.     CrossRef
• Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate and repaglinide in tablets
  Marianne A. Mahrouse, Nesrine T. Lamie
  Microchemical Journal.2019; 147: 691.     CrossRef
• The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea
  Da Young Lee, Ji Hee Yu, Sanghyun Park, Kyungdo Han, Nam Hoon Kim, Hye Jin Yoo, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim, Ji A. Seo
  Scientific Reports.2018;[Epub]     CrossRef
• Effect of Lifestyle Modification and Oral Anti-Diabetic Drugs on Metabolic Parameters in Recently Diagnosed Patientswith Uncomplicated Type 2 Diabetes Mellitus in Eastern India
  Nikhilesh Pradhan, Sidhartha Das, Anoj Kumar Baliarsinha, Ashirbad Parhi, Bijan Patnaik, Pramod Kumar Rout
  Journal of Diabetes Mellitus.2018; 08(02): 9.     CrossRef
• Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program
  Ja Young Jeon, Soo Jin Lee, Sieun Lee, Soo Jin Kim, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Young Seol Kim, Jeong Taek Woo, Kyu Jeung Ahn, Moonsuk Nam, Sei Hyun Baik, Yongsoo Park, Kwan‐Woo Lee
  Journal of Diabetes Investigation.2018; 9(5): 1144.     CrossRef